NCT06757634Phase 3Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Study sponsor: Celcuity Inc · CELC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03-31Estimated
Enrollment · participants1180Estimated
Source updated2026-10-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 506 participants

Before: 674 participants (planned). After: 1180 participants (planned).

Primary completion date changed

Before: 31 Dec 2027. After: 31 Mar 2029.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview